For a child born with a faulty heart valve, the first surgery is rarely the last. The mechanical or animal-tissue replacements used today are not designed to grow with a young patient, and they carry a lifetime risk of rejection, clotting, or failure. The clinical reality is a series of high-risk, open-heart operations, each one more complex than the last. A Berlin-based startup, GrownValve, is now moving a different kind of replacement from the lab into people, one built to integrate and last a lifetime. In June 2025, the company announced the first human implantation of its regenerative, autologous heart valve, a milestone that shifts its work from preclinical research into the long, careful path of clinical validation [GrownValve, June 2025].
The patient-specific scaffold
GrownValve's core innovation is a scaffold, shaped from a patient's own imaging data, that the body is meant to colonize with its own cells. The company's process begins with a 3D scan of a patient's heart. Using that data, engineers create a patient-specific, bioresorbable scaffold. During a transcatheter procedure, this scaffold is implanted. The idea is that the patient's own endothelial cells will then migrate onto the structure, gradually building a living, functional valve as the scaffold dissolves [GrownValve, Unknown]. The resulting tissue, the company posits, should be recognized as 'self' by the immune system, eliminating the need for lifelong anticoagulation therapy and, critically, allowing the valve to grow and remodel over time [LinkedIn, 2026].
This approach targets a fundamental limitation in current pediatric and adult cardiac care. For Boris Schmitt, GrownValve's CEO and a pediatric cardiologist at Berlin's Charité hospital, the clinical need is personal. The company is a formal spin-off from the Charité and the German Heart Center Berlin, grounding its research in direct hospital experience [GrownValve, June 2025]. The first-in-human procedure, while a single data point, represents a critical de-risking step for the platform technology.
A foundation of non-dilutive capital
GrownValve's journey from academic project to clinical-stage company has been propelled significantly by European public and grant funding, a common and strategic path for deep-tech life sciences ventures on the continent. The company's total disclosed funding stands at approximately $8.13 million, with the bulk coming from a $7.99 million Early Stage VC round in September 2022 [PitchBook, Unknown].
What stands out is the composition of its backers and the staged, grant-heavy approach to early development.
| Funding Source | Type | Approximate Amount | Purpose / Note |
|---|---|---|---|
| Early Stage VC (Sep 2022) | Equity | $7.99M | Lead investor not specified [PitchBook, Unknown] |
| EIC Accelerator | Grant | Up to €2.5M | European Innovation Council support [zabala.eu, 2026] |
| EXIST II | Grant | Not Disclosed | One-year grant for establishing Quality & Risk Management systems [grownvalve.de, 2026] |
| German Federal Ministry of Education and Research | Grant | Not Disclosed | Awarded in November 2021 [GrownValve, Unknown] |
This capital structure highlights a focus on derisking the science before seeking large-scale venture rounds. Investors listed include the European Innovation Council Fund and the Innovation Network for Advanced Materials, entities that typically bet on deep-tech with strong translational potential [PitchBook, Unknown]. The grant funding, particularly for quality management systems, signals an early operational focus on the rigorous documentation required for eventual regulatory filings.
The long road to the clinic
The first human implantation is a beginning, not an end. The path for a novel, autologous implantable device through European (EMA) and American (FDA) regulatory bodies is measured in years, not months. GrownValve will need to design and execute controlled clinical studies to demonstrate not just safety, but superior long-term outcomes compared to the standard of care. The company's platform also introduces manufacturing complexity; creating a patient-specific device within a clinically viable timeframe adds a layer of operational challenge that batch-produced valves do not face.
Competition in the heart valve space is well-funded and decades old. Established giants like Edwards Lifesciences and Medtronic dominate the market for transcatheter valves. GrownValve's nearer-term peers are other ventures aiming to improve durability through tissue engineering or novel materials.
- Xeltis. A Dutch-Swiss company developing bioresorbable synthetic heart valves. Its approach also uses a scaffold designed to be replaced by the patient's own tissue, but it is not customized to individual anatomy [Competitor].
- Foldax. An American company producing a polymer-based, robotically manufactured heart valve designed to be durable and avoid the need for anticoagulants. Its Tria valve is not autologous [Competitor].
GrownValve's wedge is the combination of personalization and autologous regeneration. The bet is that this dual advantage will justify the added complexity and cost, particularly for the pediatric population where growth is a non-negotiable requirement.
What standard of care looks like today
For the hundreds of thousands of patients worldwide requiring heart valve replacement each year, the current options present a series of difficult trade-offs. Mechanical valves are durable but require lifelong blood-thinning medication, which carries its own risks of bleeding and complicates pregnancy and other surgeries. Bioprosthetic valves, made from animal tissue, do not require anticoagulants but are prone to calcification and deterioration, often requiring reoperation within 10 to 15 years. For children, this is especially punishing; a valve that cannot grow guarantees repeated, traumatic open-heart procedures. The clinical ideal a valve that is durable, biocompatible, and capable of growth has remained out of reach. GrownValve's work, now moving into human studies, is a direct attempt to resolve that decades-old compromise.
The next twelve months
The immediate focus for the Berlin team will be on gathering and analyzing data from its initial patients. The next milestones are clinical, not financial: demonstrating early safety and valve functionality, and then designing the pivotal studies that will form the backbone of a regulatory submission. The company's grant-heavy, academically rooted start has given it a long runway to prove its concept. The coming phase will test whether its patient-grown valve can transition from a compelling biomedical thesis to a reproducible, scalable, and reimbursable therapy. For the children and adults living with the limitations of today's artificial valves, that proof cannot come soon enough.
Sources
- [GrownValve, June 2025] Press Release: First human implantation of regenerative heart valve | http://grownvalve.com/news/GrOwnValve%20Press%20Release%20Final%20Version%20English%2020250627.pdf
- [GrownValve, Unknown] Company website and product description | https://grownvalve.com/
- [PitchBook, Unknown] GrownValve funding and investor information
- [zabala.eu, 2026] EIC Accelerator grant details | https://zabala.eu/company/grownvalve/
- [grownvalve.de, 2026] EXIST II funding announcement | https://grownvalve.de/
- [LinkedIn, 2026] Company description and technology claims
- [Competitor] Public competitor analysis